Public Library of Science
Browse
Figure_6.tif (6.39 MB)

Effect of gefitinib on bleomycin-induced pulmonary fibrosis and pulmonary expression of HSP70.

Download (0 kB)
figure
posted on 2011-11-09, 01:28 authored by Takushi Namba, Ken-Ichiro Tanaka, Tatsuya Hoshino, Arata Azuma, Tohru Mizushima

Wild-type mice (A, B, E, G, H) and transgenic mice expressing HSP70 (C, D, F, G, J) were orally administered gefitinib (200 mg/kg) or vehicle once per day for 3 days (from day 0 to day 2), then treated once only with or without 1 mg/kg (for wild-type mice) or 2 mg/kg (for the transgenic mice) bleomycin (BLM) (day 3). Mice were then orally administered gefitinib (200 mg/kg) or vehicle once per 2 days for 14 days (from day 3 to day 17). Sections of pulmonary tissue were prepared at day 17 and subjected to histological examination (H & E staining (A, C) or Masson's trichrome staining (B, D)) (scale bar, 50 µm) (A-D). Pulmonary hydroxyproline levels at day 17 were determined (E, F). Total protein was extracted from pulmonary tissues at day 17 and analyzed by immunoblotting with an antibody against HSP70 or actin (G, H, J). The intensities of the HSP70 bands were determined (one of the gels is shown in H) and are expressed relative to the control (I). Values are mean ± S.E.M. *P<0.05; **P<0.01; n.s., not significant.

History

Usage metrics

    PLOS ONE

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC